Reumatología Clínica

Reumatología Clínica

Volume 15, Issue 1, January–February 2019, Pages 34-42
Reumatología Clínica

Original article
Pure Membranous Lupus Nephritis: Description of a Cohort of 150 Patients and Review of the LiteratureNefritis lúpica membranosa pura: descripción de una cohorte de 150 pacientes y revisión de la literatura

https://doi.org/10.1016/j.reuma.2017.04.005Get rights and content

Abstract

Objectives

The course and long-term outcome of pure membranous lupus nephritis (MLN) are little understood. The aims of this study are to evaluate the clinical features, course, outcome and prognostic indicators in pure MLN and to determine the impact of ethnicity and the type of health insurance on the course and prognosis of pure MLN.

Methods

We conducted a retrospective review of medical records of 150 patients with pure MLN from Spain and the USA.

Results

Mean age was 34.2 ± 12.5 and 80% were women. Sixty-eight percent of patients had nephrotic syndrome at diagnosis. The average serum creatinine was 0.98 ± 0.78 mg/dl. Six percent of patients died and 5.3% developed end-stage renal disease (ESRD). ESRD was predicted by male sex, hypertension, dyslipidemia, high basal 24 h-proteinuria, high basal serum creatinine and a low basal creatinine clearance. Age, cardiac insufficiency, peripheral artheriopathy, hemodialysis and not having received mycophenolate mofetil or antimalarials for MLN predicted death.

Conclusions

Pure MLN frequently presents with nephrotic syndrome, high proteinuria and normal serum creatinine. Its prognosis is favourable in maintaining renal function although proteinuria usually persists over time. Baseline cardiovascular disease and not having a health insurance are related with poor prognosis.

Resumen

Objetivos

Los conocimientos sobre el curso y el desenlace a largo plazo de la nefritis lúpica membranosa (NLM) pura son todavía escasos. El objetivo de este estudio es evaluar las características clínicas, curso, desenlace e indicadores pronósticos de la NLM y determinar el impacto de la etnicidad y tipo de cobertura sanitaria en el curso y pronóstico de la NLM.

Métodos

Se realizó una revisión retrospectiva de las historias de 150 pacientes con NLM de España y Estados Unidos.

Resultados

La edad media fue 34,2 ± 12,5 y el 80% eran mujeres. El 68% de los pacientes tenían síndrome nefrótico al diagnóstico. La creatinina sérica media fue 0,98 ± 0,78 mg/dl. El 6% de los pacientes fallecieron y el 5,3% desarrollaron insuficiencia renal terminal (IRT). El sexo masculino, la hipertensión, la dislipemia, la alta proteinuria basal, la alta creatininemia y un aclaramiento de creatinina reducido predijeron el desarrollo de IRT. La edad, la insuficiencia cardíaca, la arteriopatía periférica, la hemodiálisis y el no haber recibido micofenolato de mofetilo o antimaláricos predijeron el fallecimiento.

Conclusiones

La NLM pura suele debutar con síndrome nefrótico, alta proteinuria y creatininemia normal. Su pronóstico es favourable en términos de mantenimiento de la función renal aunque la proteinuria habitualmente persiste durante el seguimiento. La enfermedad cardiovascular basal y no tener cobertura sanitaria se relacionan con mal pronóstico.

Introduction

Over 50% of patients with systemic lupus erythematosus (SLE) have clinically significant renal involvement during the course of their disease. Approximately 8–20% of these are found on renal biopsy to have membranous lupus nephropathy (MLN).1, 2 Pure MLN has distinct histologic features compared to proliferative lupus nephritis.3 This difference is reflected in the clinical presentations of proliferative and membranous lupus nephritis, with the former being dominated by a nephritic process whereas MLN is characterised predominantly by nephrotic syndrome.1, 4, 5

Few studies have addressed the course and outcome of MLN directly,4, 6, 7, 8, 9, 10, 11, 12, 13, 14 and their results are contrasting. Most of our knowledge is derived from extrapolations of data of idiopathic membranous nephritis and/or proliferative lupus nephritis. Research on MLN frequency, natural history, prognosis and treatment was further limited due to a lack of uniform definition over the past several decades, making it difficult to get consistent information from the published literature about MLN.1

An Italian study15 has reported the outcome in 103 patients with MLN, but a third of them had mixed forms. More recently, Mejía-Vilet et al.13 have reported the results of a cohort of 60 Hispanic and Mexican-mestizo patients with pure MLN suggesting an impact of ethnicity on the response to different immunosuppressants (azathioprine, cyclophosphamide or mycophenolate).

Large cohorts of patients with pure MLN are lacking, and to date the influence of ethnicity and social conditions on pure MLN outcome has rarely been studied.

The aims of the present study are to evaluate the clinical features, course, outcome and prognostic indicators in pure MLN and to explore the association of ethnicity, socio-economic level, country of residence and the type of health insurance with the course and prognosis of pure MLN.

Section snippets

Patients

This multicentre, retrospective clinicopathologic study evaluated 150 patients with biopsy-proven Class Va pure MLN (modified WHO classification) who underwent renal biopsies between 1978 and 2011 in 24 hospitals in Spain and 1 in the United States. With the aim of gathering a large number of pure MLN patients and taking into account its low prevalence, we chose to include patients diagnosed in a broad temporal range and from different geographical areas. The registers of renal biopsies of each

Comparison Between Both Cohorts

Of the 150 patients included in the analysis, 48 were followed-up in the Hospital for Joint Diseases of New York and 102 in the rheumatology departments of 24 different hospitals in Spain. The clinical characteristics at MLN presentation, administered treatments at any point during the course of the disease and outcome of both cohorts are displayed in Table 1, Table 2, Table 3. Statistically significant differences between both cohorts were found regarding ethnicity distribution, type of health

Discussion

In this study, we retrospectively analysed the baseline and long-term follow-up characteristics of a cohort of 150 patients with pure MLN. Unlike many other studies, we excluded patients with mixed forms of membranous nephritis. There are only a few studies concerning pure MLN, and the conclusions about the presentation and natural course are unclear. This is possibly a consequence of the difficulties to identify histologically pure forms of MLN according to the different classifications and

Conclusion

MLN usually begins with nephrotic syndrome, high proteinuria and normal serum creatinine. Prognosis is favourable in terms of the maintenance of renal function, although proteinuria usually persists over time. Patient and renal survival are high in patients with pure types of MLN but severity at presentation predicts a poor long-term outcome in terms of ESRD. Other factors such as baseline cardiovascular disease and not having a health insurance are also related with poor prognosis.

Protection of human and animal subjects

The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data

The authors declare that no patient data appear in this article.

Right to privacy and informed consent

The authors declare that no patient data appear in this article.

Funding

This study had no funding source or sponsor.

Ethics approval: Ethical approval for this study was obtained in February 2011 from the Hospital Universitario Puerta de Hierro Majadahonda of Madrid, Spain.

Conflicts of Interest

The authors declare no conflicts of interest.

References (58)

  • A.A. Bakir et al.

    The prognosis of lupus nephritis in African-Americans: a retrospective analysis

    Am J Kidney Dis.

    (1994)
  • H.A. Austin et al.

    Membranous lupus nephritis

    Lupus

    (2005)
  • C.C. Mok

    Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma

    Nat Rev Nephrol

    (2009)
  • S.L. Kolasinski et al.

    What do we know about lupus membranous nephropathy. An analytic review

    Arthritis Rheum

    (2002)
  • H. Ikeuchi et al.

    Renal outcomes in mixed proliferative and membranous lupus nephritis (Class III/IV + V): a long-term observational study

    Mod Rheumatol

    (2016)
  • S. Gordon et al.

    Success using tacrolimus in patients with proliferative and membranous lupus nephritis and refractory proteinuria

    Hawaii J Med Public Health

    (2013)
  • T.M. Chan et al.

    Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression

    Lupus

    (1999)
  • J. Radhakrishnan et al.

    Cyclosporine treatment of lupus membranous nephropathy

    Clin Nephrol

    (1994)
  • S. Pasquali et al.

    Lupus membranous nephropathy: long-term outcome

    Clin Nephrol

    (1993)
  • S.G. Adler et al.

    Lupus membranous glomerulonephritis: different prognostic subgroups obscured by imprecise histologic classifications

    Mod Pathol

    (1990)
  • B. Leaker et al.

    Lupus nephritis: clinical and pathological correlation

    Q J Med

    (1987)
  • J.M. Mejia-Vilet et al.

    Immunosuppressive treatment for pure membranous lupus nephropathy in a Hispanic population

    Clin Rheumatol

    (2016)
  • C.C. Szeto et al.

    Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis

    Rheumatology (Oxford)

    (2008)
  • E.M. Tan et al.

    The 1982 revised criteria for the classification of systemic lupus erythematosus

    Arthritis Rheum

    (1982)
  • M.C. Hochberg

    Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

    Arthritis Rheum

    (1997)
  • G.B. Appel et al.

    Renal involvement in systemic lupud erythematosus (SLE): a study of 56 patients emphasizing histologic classification

    Medicine (Baltimore)

    (1978)
  • M.M. Schwartz et al.

    Clinical and pathological features of membranous glomerulonephritis of systemic lupus erythematosus

    Am J Nephrol

    (1984)
  • G. Moroni et al.

    Rituximab versus oral cyclophosphamide for treatment of relapses of proliferative lupus nephritis: a clinical observational study

    Ann Rheum Dis

    (2012)
  • J.V. Donadio et al.

    Membranous lupus nephropathy: a clinicopathologic study

    Medicine (Baltimore)

    (1977)
  • View full text